SCHEMBL4170573

SCHEMBL4170573

Cc1cc(Nc2cnc(-c3ccc(Cl)c(NC(C)C)c3)c(N)n2)n[nH]1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NTRK1 P04629 4/20 0.40
▸ JAK2 O60674 10/20 0.40
▸ JAK3 P52333 9/20 0.40
▸ MEN1 O00255 1/20 0.39
▸ HTT P42858 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.39
▸ AURKA O14965 4/20 0.39
▸ AURKB Q96GD4 3/20 0.39
▸ RET P07949 3/20 0.39
▸ PLK4 O00444 2/20 0.39
▸ PAK4 O96013 2/20 0.39
▸ STK10 O94804 1/20 0.39
▸ FGFR1 P11362 1/20 0.39
▸ FER P16591 1/20 0.39
▸ CSNK2A2 P19784 1/20 0.39
▸ JAK1 P23458 1/20 0.39
▸ TYK2 P29597 1/20 0.39
▸ FLT3 P36888 1/20 0.39
▸ STAT3 P40763 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4159458 0.90 JAK2 (0.41) NTRK1JAK2JAK3MEN1HTT
SCHEMBL4167301 0.88 JAK2 (0.44) NTRK1JAK2JAK3AURKAAURKB
SCHEMBL4168909 0.86 IKBKB (0.46) NTRK1JAK2JAK3MEN1HTT
SCHEMBL4171046 0.85 PLK4 (0.41) NTRK1JAK3MEN1HTTKMT2A
SCHEMBL4169281 0.85 MEN1 (0.43) NTRK1JAK2JAK3MEN1HTT
SCHEMBL4168663 0.83 AURKB (0.43) NTRK1JAK2JAK3MEN1HTT
SCHEMBL4179012 0.82 MEN1 (0.46) NTRK1JAK2JAK3MEN1HTT
SCHEMBL4171086 0.82 NPC1 (0.41) NTRK1JAK2JAK3MEN1HTT
SCHEMBL4166686 0.81 DHODH (0.40) NTRK1JAK2JAK3MEN1HTT
SCHEMBL4171713 0.80 IGF1R (0.40) NTRK1MEN1HTTKMT2AHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090270418-A1 PYRAZOLE PYRAZINE AMINE COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS THEREOF AND METHODS OF TREATMENT THEREWITH SIGNAL PHARMACEUTICALS, LLC 2009-10-29 — — US claimed
WO-2009089042-A1 PYRAZOLE PYRAZINE AMINE COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS THEREOF AND METHODS OF TREATMENT THEREWITH SIGNAL PHARMACEUTICALS, LLC (US) 2009-07-16 — — WO claimed
US-20090270418-A1 PYRAZOLE PYRAZINE AMINE COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS THEREOF AND METHODS OF TREATMENT THEREWITH SIGNAL PHARMACEUTICALS, LLC 2009-10-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270418-A1 PYRAZOLE PYRAZINE AMINE COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS THEREOF AND METHODS OF TREATMENT THEREWITH MAP3K1, MAP3K15, MAP3K5 NTRK1 2610/4885JAK2 39/4885JAK3 35/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback